BrainsWay Announces Social Media Sweepstakes to Celebrate Mental Health Awareness Month
04 Maggio 2021 - 3:02PM
BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the
“Company”), a global leader in the advanced noninvasive treatment
of brain disorders, today announced the launch of its nationwide
Sweepstakes, in conjunction with Mental Health Awareness Month.
Participants can enter throughout the month of May for a chance to
be one of 20 winners to receive a curated self-care package.
The goal of the Sweepstakes is to demonstrate
how Deep Transcranial Magnetic Stimulation (Deep TMS) can easily
fit into an average day, by featuring 20-minute tasks that can be
completed in the same amount of time it takes to undergo a Deep TMS
treatment session for major depressive disorder (MDD) or
obsessive-compulsive disorder (OCD). Select brand ambassadors,
including mental health advocates Rachel Novak (@rachel.novak) and
Anna Russett (@anna.russett), who partnered with the Company for
its “#TheRealOCD” campaign, along with Amy Tran (@doodledwellness)
and Shelly-ann Shaw (the_depression_chronicles11), will also
promote the Sweepstakes throughout the month to further awareness
of the treatment.
“We view social media as a powerful platform to
foster conversations around mental health and treatment options,
and due to the COVID-19 pandemic, believe there are many new
patients living with mental illness who can benefit greatly from
knowing there is hope and they are not alone,” said Christopher von
Jako, Ph.D., President and CEO of BrainsWay. “It is our mission to
empower patients to know about noninvasive treatment options,
especially ones that can be integrated into busy schedules and that
can work around daily commitments, like Deep TMS.”
BrainsWay’s Deep TMS device noninvasively
administers magnetic waves through a cushioned helmet to target
deep structures of the brain that impact depression and OCD
symptoms. The treatment offers a medication-free solution, and
patients can return to normal activities, such as driving,
immediately following the 20-minute sessions. BrainsWay Deep TMS
received FDA clearance for the treatment of depression in 2013 and
for the treatment of OCD in 2018.
To enter the Sweepstakes, participants must
follow BrainsWay on Facebook, Twitter, and/or Instagram, and
tag one friend on a designated Sweepstakes post to help raise
awareness around Deep TMS. For more on the prize and how to enter
visit go.brainsway.com/MentalHealthAwarenessMonth.
About BrainsWayBrainsWay is a
global leader in advanced noninvasive neurostimulation treatments
for mental health disorders. The Company is boldly advancing
neuroscience with its proprietary Deep Transcranial Magnetic
Stimulation (Deep TMS) platform technology to improve health and
transform lives. BrainsWay is the first and only TMS company to
obtain three FDA-cleared indications backed by pivotal studies
demonstrating clinically proven efficacy. Current indications
include major depressive disorder, obsessive-compulsive disorder,
and smoking addiction. The Company is dedicated to leading through
superior science and building on its unparalleled body of clinical
evidence. Additional clinical trials of Deep TMS in various
psychiatric, neurological, and addiction disorders are underway.
Founded in 2003, with offices in Cresskill, NJ and Jerusalem,
Israel, BrainsWay is committed to increasing global awareness and
broad access to Deep TMS. For the latest news and information about
BrainsWay, please visit www.brainsway.com.
Forward Looking Statements
This press release contains "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Such statements may be preceded by the words
“intends,” “may,” “will,” “plans,” “expects,” “anticipates,”
“projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,”
“potential” or similar words, and include, but are not limited to,
statements about the expected proceeds, use of proceeds and closing
of the underwritten offering. These forward-looking statements and
their implications are based on the current expectations of the
management of the Company only and are subject to a number of
factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.
The following factors, among others, could cause actual results to
differ materially from those described in the forward-looking
statements: inadequacy of financial resources to meet future
capital requirements; changes in technology and market
requirements; delays or obstacles in launching and/or successfully
completing planned studies and clinical trials; failure to obtain
approvals by regulatory agencies on the Company’s anticipated
timeframe, or at all; inability to retain or attract key employees
whose knowledge is essential to the development of Deep TMS
products; unforeseen difficulties with Deep TMS products and
processes, and/or inability to develop necessary enhancements;
unexpected costs related to Deep TMS products; failure to obtain
and maintain adequate protection of the Company’s intellectual
property, including intellectual property licensed to the Company;
the potential for product liability; changes in legislation and
applicable rules and regulations; unfavorable market perception and
acceptance of Deep TMS technology; inadequate or delays in
reimbursement from third-party payers, including insurance
companies and Medicare; inability to commercialize Deep TMS,
including internationally, by the Company or through third-party
distributors; product development by competitors; inability to
timely develop and introduce new technologies, products and
applications, and the effect of the global COVID-19 health pandemic
on our business and continued uncertainty and market impact
relating thereto.
Any forward-looking statement in this press
release speaks only as of the date of this press release. The
Company undertakes no obligation to publicly update or review any
forward- looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by any
applicable securities laws. More detailed information about the
risks and uncertainties affecting the Company is contained under
the heading “Risk Factors” in the Company’s filings with the U.S.
Securities and Exchange Commission, including the Company's Annual
Report on Form 20-F. Investors and security holders are urged to
read these documents free of charge on the SEC’s web site at
http://www.sec.gov.
BrainsWay Media Contact:Will
JohnsonBrainsway@antennagroup.com(201) 465-8019
Grafico Azioni Brainsway (NASDAQ:BWAY)
Storico
Da Set 2024 a Ott 2024
Grafico Azioni Brainsway (NASDAQ:BWAY)
Storico
Da Ott 2023 a Ott 2024